API | catumaxomab

catumaxomab (Removab) Report issue

Biologics mAb Multi-specific Experimental

AACT ChEMBL

Active Ingredient History

NOW

Catumaxomab is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
catumaxomab

More Chemistry

Pharmacology

Mechanisms of Action:
- Epithelial cell adhesion molecule (Homo sapiens) ^UniProt
- High affinity immunoglobulin gamma Fc receptor I (Homo sapiens) ^UniProt
- Low affinity immunoglobulin gamma Fc region receptor III-A (Homo sapiens) ^UniProt
- T-cell surface glycoprotein CD3 epsilon chain (Homo sapiens) ^UniProt
- Epithelial cell adhesion molecule (Homo sapiens) ^UniProt
Multi-specific: Yes
Black Box: No
Availability: Missing data
Delivery Methods: Parenteral
Pro Drug: No

catumaxomab | removab

Organizations (24)

Research & Development (24)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Ascites (Phase 3)

Breast Neoplasms (Phase 2/Phase 3)

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Neoplasms ()

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 17
# of Trial Organizations: 24

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue